March 27, 2019 Mental Health News

On March 5th the U.S. Food and Drug Administration approved a new nasal spray treatment called Spravato (esketamine) in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression).

Patients with a major depressive disorder who, despite trying at least two antidepressant treatments given at adequate doses for an adequate duration in the current episode, have not responded to treatment are considered to have treatment-resistant depression.

Copyright © 2008-2018. All rights reserved | Website services by WebWorkz